Haemonetics Quarterly Cash Flow Statement
NYSE: HAEHealth CareMedical/Dental InstrumentsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Haemonetics free cash flow
In the quarter ended Jun 27, 2026, Haemonetics generated $52.3 million of operating cash flow and spent $7.9 million on capital expenditures. That left free cash flow of $44.4 million, a free-cash-flow margin of 13.1% of revenue. Free cash flow was up 225.6% from the prior year's $13.6 million.
Summary generated from market data by MetaCap's automated system. Methodology
Haemonetics cash flow statement (quarterly)
| Quarter (USD) | Q1 20272026-06-27 | Q4 20262026-03-28 | Q3 20262025-12-27 | Q2 20262025-09-27 | Q1 20262025-06-28 | Q4 20252025-03-29 | Q3 20252024-12-28 | Q2 20252024-09-28 | Q1 20252024-06-29 | Q4 20242024-03-30 | Q3 20242023-12-30 | Q2 20242023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 33.01M | -20.15M | 44.74M | 38.68M | 34.03M | 57.98M | 37.49M | 33.83M | 38.37M | 20.37M | 31.24M | 24.91M |
| Net Income growth (YoY) | -3.00% | -134.75% | +19.33% | +14.34% | -11.32% | +184.68% | +20.02% | +35.82% | -6.50% | -30.68% | -5.17% | -24.97% |
| Depreciation & Amortization | 27.11M | 27.32M | 27.39M | 28.25M | 28.76M | 28.21M | 29.02M | 29.22M | 29.14M | 27.64M | 23.53M | 23.01M |
| Stock-Based Compensation | 9.31M | 9.13M | 7.80M | 7.59M | 9.31M | 6.94M | 8.21M | 6.86M | 7.63M | 7.42M | 7.22M | 6.71M |
| Change in Working Capital | -13.32M | 6.55M | 18.20M | 32.20M | -41.04M | 27.58M | -15.79M | -16.38M | -72.36M | 33.73M | -64.37M | 34.28M |
| Operating Cash Flow | 52.32M | 70.94M | 93.56M | 111.32M | 17.39M | 116.56M | 43.77M | 48.82M | -27.42M | 64.08M | -540.00K | 99.12M |
| Capital Expenditures | -7.91M | -17.66M | -6.35M | -5.02M | -3.75M | -15.64M | -8.55M | -9.43M | -5.66M | -6.68M | -14.65M | -9.11M |
| Investing Cash Flow | -22.23M | -86.61M | -29.47M | -30.47M | -33.00M | 18.04M | -17.37M | -23.37M | -139.20M | -13.06M | -268.94M | -25.14M |
| Share Repurchases | — | -100.00M | 0 | — | — | -150.00M | 0 | — | — | 0 | 0 | — |
| Debt Repaid | -1.56M | — | -1.56M | -1.56M | -1.56M | -1.56M | -1.56M | 0 | -1.56M | -3.50M | -3.50M | -3.50M |
| Financing Cash Flow | -51.53M | -101.50M | 2.03M | -76.55M | -2.44M | -151.45M | 1.38M | -74.80M | 333.69M | -63.50M | 109.43M | -7.17M |
| Net Change in Cash | -22.06M | -117.93M | 66.94M | 3.53M | -13.87M | -14.08M | 21.56M | -45.15M | 165.63M | -15.18M | -157.03M | 65.29M |
| Free Cash Flow | 44.42M | 53.28M | 87.22M | 106.31M | 13.64M | 100.91M | 35.22M | 39.39M | -33.08M | 57.40M | -15.19M | 90.01M |
This table shows 12 quarterly periods of Haemonetics's cash flow statement, from Q1 2027 back to Q2 2024, across 13 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow HAE's reporting calendar. What is a cash flow statement?